Yuyu Pharma, Inc. (KRX:000220)
South Korea · Delayed Price · Currency is KRW 4,130.00
+45.00 (1.10%)
Apr 8, 2026, 3:30 PM KST
Yuyu Pharma Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 8,154 | 8,720 | -7,181 | -5,988 | -2,214 |
Depreciation & Amortization | 5,608 | 5,666 | 5,607 | 5,027 | 4,503 |
Loss (Gain) From Sale of Assets | -16.7 | -1,249 | 98.3 | 248.79 | 3.23 |
Asset Writedown & Restructuring Costs | - | 349.46 | 579.75 | 241.38 | - |
Loss (Gain) From Sale of Investments | 267.07 | 370.71 | -657.78 | -182.69 | 139.24 |
Loss (Gain) on Equity Investments | -571.43 | -68.58 | 493.69 | -395.07 | -548.18 |
Stock-Based Compensation | - | - | - | - | -42.4 |
Provision & Write-off of Bad Debts | -149.3 | -589.56 | 391.86 | -413.97 | 420.18 |
Other Operating Activities | 4,178 | 4,539 | 7,861 | 8,384 | 5,951 |
Change in Accounts Receivable | -741.72 | 2,839 | 1,689 | -2,152 | -1,876 |
Change in Inventory | -4,205 | 5,913 | -3,424 | -15,134 | -1,367 |
Change in Accounts Payable | -69.62 | -1,615 | -5,527 | 7,091 | 3,716 |
Change in Other Net Operating Assets | 3,425 | 73.36 | 490.34 | -2,956 | -4,176 |
Operating Cash Flow | 15,877 | 24,950 | 420.86 | -6,229 | 4,509 |
Operating Cash Flow Growth | -36.36% | 5828.40% | - | - | - |
Capital Expenditures | -8,253 | -7,112 | -4,514 | -5,283 | -6,073 |
Sale of Property, Plant & Equipment | 16.72 | 2,589 | 120 | 4.6 | 19.36 |
Cash Acquisitions | - | - | -890.9 | - | - |
Divestitures | - | - | - | - | 1,029 |
Sale (Purchase) of Intangibles | -201.06 | 172.05 | -591.83 | -285.08 | -677.68 |
Investment in Securities | -4,930 | -1,993 | 2,441 | -3,328 | -120.7 |
Other Investing Activities | 990.81 | 2,135 | 1,121 | 846.86 | -66.34 |
Investing Cash Flow | -12,376 | -4,009 | -2,815 | -8,544 | -5,890 |
Long-Term Debt Issued | - | 3,200 | 37,060 | 2,100 | 35,000 |
Total Debt Issued | - | 3,200 | 37,060 | 2,100 | 35,000 |
Long-Term Debt Repaid | -11,966 | -12,230 | -27,349 | -6,984 | -1,610 |
Total Debt Repaid | -11,966 | -12,230 | -27,349 | -6,984 | -1,610 |
Net Debt Issued (Repaid) | -11,966 | -9,030 | 9,711 | -4,884 | 33,390 |
Repurchase of Common Stock | -1,998 | - | - | -1,785 | - |
Dividends Paid | -1,929 | - | -2,002 | -2,034 | -1,851 |
Other Financing Activities | -583.72 | -829.85 | -549.13 | -380.04 | -225.42 |
Financing Cash Flow | -16,477 | -9,860 | 7,160 | -9,083 | 31,313 |
Foreign Exchange Rate Adjustments | 233.92 | 146.16 | 0.01 | -568.86 | 8.58 |
Miscellaneous Cash Flow Adjustments | 0 | -0 | 0 | - | - |
Net Cash Flow | -12,742 | 11,228 | 4,766 | -24,425 | 29,941 |
Free Cash Flow | 7,625 | 17,838 | -4,094 | -11,512 | -1,565 |
Free Cash Flow Growth | -57.26% | - | - | - | - |
Free Cash Flow Margin | 5.41% | 13.40% | -2.98% | -8.29% | -1.35% |
Free Cash Flow Per Share | 449.76 | 1049.38 | -251.63 | -694.28 | -98.04 |
Cash Interest Paid | 593.63 | 829.85 | 549.13 | 380.04 | 225.42 |
Cash Income Tax Paid | 1,638 | 1,570 | 517.96 | 373.41 | -25.35 |
Levered Free Cash Flow | -2,378 | 21,172 | -7,527 | -12,176 | -1,351 |
Unlevered Free Cash Flow | -827.44 | 23,184 | -5,931 | -10,563 | 8.33 |
Change in Working Capital | -1,592 | 7,212 | -6,773 | -13,151 | -3,704 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.